Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) Short Interest Update

Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) saw a large growth in short interest during the month of June. As of June 30th, there was short interest totalling 17,300 shares, a growth of 188.3% from the June 15th total of 6,000 shares. Based on an average daily volume of 170,600 shares, the short-interest ratio is presently 0.1 days.

Chugai Pharmaceutical Stock Down 0.8 %

Chugai Pharmaceutical stock traded down $0.16 during mid-day trading on Thursday, hitting $19.79. The company’s stock had a trading volume of 46,914 shares, compared to its average volume of 131,873. Chugai Pharmaceutical has a twelve month low of $13.47 and a twelve month high of $22.61. The stock’s fifty day moving average price is $16.41 and its two-hundred day moving average price is $17.90. The stock has a market capitalization of $65.11 billion, a P/E ratio of 29.10 and a beta of 0.87.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last announced its earnings results on Wednesday, April 24th. The company reported $0.15 earnings per share (EPS) for the quarter. Chugai Pharmaceutical had a return on equity of 20.44% and a net margin of 31.49%. The company had revenue of $1.60 billion for the quarter. Equities analysts expect that Chugai Pharmaceutical will post 0.7 earnings per share for the current year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.